Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects

NCT07049107 | Completed Phase 1

• 1 other identifier: HRS-8427-105
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a single-center, open-label, sequential drug interaction study The primary objectives are: To evaluate the pharmacokinetic effects of HRS-8427 injection on the liver drug enzymes CYP2B6 substrate bupropion and CYP3A4 substrate midazolam in healthy subjects.

Conditions

Health Volunteer

Outcome Measures

Primary Outcomes (4)

• Cmax

  Bupropion, hydroxybupropion and midazolam, hydroxymidazolam. Observed maximum plasma concentration. Blood samples will be collected.

  15 Days

• AUC0-t

  Bupropion, hydroxybupropion and midazolam, hydroxymidazolam. Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration. Blood samples will be collected.

  15 Days

• AUC0-∞

  Bupropion, hydroxybupropion and midazolam, hydroxymidazolam. Area under the plasma concentration-time curve from time 0 to infinity. Blood samples will be collected.

  15 Days

• Tmax

  Bupropion, hydroxybupropion and midazolam, hydroxymidazolam. Observed time to reach Cmax. Blood samples will be collected.

  15 Days

Study Arms (1)

HRS-8427

EXPERIMENTAL

Drug: HRS-8427

Interventions

HRS-8427 DRUG

HRS-8427

HRS-8427

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy subjects aged 18 to 45 years old (including 18 and 45 years old, based on the time of signing the informed consent form), both male and female.
• The weight of female subjects was ≥45 kg, the weight of male subjects was ≥50 kg, and the body mass index (BMI) was within the range of 19.0-26.0 kg/m2
• The female subjects were not in the pregnancy or lactation period, and the pregnancy examination results before the test were negative; Male or female subjects agreed to take the investigator-approved effective contraceptive measures during the trial as required by the investigator.
• Before the trial, a thorough understanding of the nature, significance, potential benefits, possible inconveniences and potential risks of the trial was obtained. The participant voluntarily participated in this clinical trial, was able to communicate well with the researcher, comply with the requirements of the entire study, and signed a written informed consent form.

You may not qualify if:

• Those with a history of allergies to food, drugs, etc., especially those known to be allergic to β -lactam antibacterial drugs and midazolam, bupropion, or those with an allergic constitution.
• Have had or are currently suffering from diseases of the heart, liver, kidneys, endocrine system, digestive tract, immune system, respiratory system, musculoskeletal system and nervous system, etc.
• Conforming to the contraindications of midazolam use or not suitable for midazolam use .
• Comply with the contraindications for bupropion use or are not suitable for bupropion use .
• The 12-lead electrocardiogram was abnormal and was judged by the researcher as unsuitable to participate in this study .
• Laboratory tests (blood routine, urine routine, blood biochemistry, coagulation function), physical examination, vital signs (ears, blood pressure, pulse, respiration), and chest X-ray results, etc., which are judged by clinicians as abnormal and of clinical significance .
• Those with positive infectious disease tests (human immunodeficiency virus antibody, hepatitis B surface antigen, anti-hepatitis C virus antibody, anti-Treponema pallidum specific antibody).
• Those who have undergone major surgical operations within the three months prior to screening; Or those who have undergone surgery that may affect the in vivo process or safety evaluation of the studied drug; Or those who plan to undergo surgical operations during the research period.
• Those who have participated in drug clinical trials as subjects and taken the investigational drug within 3 months prior to screening, or who plan to participate in other clinical trials during this study period .
• Those who have used any inducers or inhibitors of CYP2B6 and CYP3A enzymes within one month before taking the study drug for the first time.

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

Xiangya Hospital Central South University

Changsha, Hunan, 410008, China

Location

Related Publications (1)

• Yin T, Qu B, Zhang Q, Xu S, Wu Y, Jiang H, Huang Y, Hu W. Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects. Antimicrob Agents Chemother. 2026 Mar 3:e0069425. doi: 10.1128/aac.00694-25. Online ahead of print.

  PMID: 41773934 DERIVED

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 24, 2025
• First Posted: July 3, 2025
• Study Start: June 23, 2025
• Primary Completion: July 21, 2025
• Study Completion: July 21, 2025
• Last Updated: March 16, 2026

Record last verified: 2025-06

Locations

CN (1)